This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect CTI include statements about future financial and operating results, risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with CTI's strategic platform and the development of Brostallicin, XYOTAX, pixantrone, and Zevalin in particular including, without limitation, the potential failure of Brostallicin, XYOTAX, and pixantrone to prove safe and effective for treatment of cancer, the risk that we may not be able to complete the acquisition of Zevalin due to closing conditions, or that we may not recognize the full expected value of Zevalin in future years, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling Brostallicin, XYOTAX, pixantrone, and Zevalin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
|SOURCE Cell Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved